A Phase 3 interventional study of Enoxaparin in Venous Thromboembolism (VTE), sponsored by Johns Hopkins All Children's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Johns Hopkins All Children's Hospital · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing enoxaparin in Venous Thromboembolism — 5 open to participants now, 5 under way, 2 of them phase 3. Enoxaparin · Venous Thromboembolism.
Among the 32 studies testing enoxaparin in Venous Thromboembolism, this one is the 7th largest by planned enrollment, is the only one that started in 2027, is one of 8 in phase 3, and was the 30th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →5 of the 32 studies testing enoxaparin in Venous Thromboembolism are open now, in 3 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Imperial College London · Sites in United Kingdom
Ages 18+
Yale University · Sites in United States
Ages up to 17
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 10 · Phase 4 13
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 802 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 123 across the 32 interventional studies. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 32 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins All Children's Hospital is the lead sponsor of 25 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Johns Hopkins All Children's Hospital has 2 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
2 of the studies testing enoxaparin in Venous Thromboembolism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies testing enoxaparin in Venous Thromboembolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.
This trial will establish definitive evidence on the comparative efficacy and safety of pharmacological thromboprophylaxis with the low molecular weight heparin (LMWH) enoxaparin versus no pharmacological thromboprophylaxis for the primary prevention of venous thromboembolism (VTE), including deep vein thrombosis and/or pulmonary embolism) among critically ill adolescents who meet a priori criteria for high risk of hospital-acquired (HA-) VTE. In the past two decades, the diagnosis of pediatric hospital-acquired VTE (HA-VTE) in the U.S. has increased 130-200-fold. The investigators have shown that critically-ill adolescents are one the highest risk subpopulations for HA-VTE, with average occurrence rates of 13.2% (range: 6.3-19.8%), and have derived and prospectively validated risk models for HA-VTE in this population. Despite a simultaneously increased risk of bleeding in critically ill adolescents, particularly after surgery or major trauma, an investigator-initiated multicenter phase 2 trial recently led by the investigators group during the COVID-19 pandemic demonstrated the safety of LMWH for primary HA-VTE prevention. To date, risk-stratified phase 3 Randomized Controlled Trials (RCTs) of LMWH thromboprophylaxis as primary HA-VTE prevention in children have not been performed. The investigators will perform a U.S.-based definitive multicenter phase 3 RCT of the LMWH enoxaparin versus no pharmacological thromboprophylaxis for VTE prevention among critically ill adolescents at highest a priori risk for HA-VTE applying evidence from the investigators published risk prediction models.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will receive the study intervention, enoxaparin thromboprophylaxis during pediatric intensive care unit hospitalization
Drug: Enoxaparin
This arm will receive no pharmacological thromboprophylaxis
Enoxaparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
Risk (i.e., cumulative incidence) of Symptomatic venous thromboembolism
International Society on Thrombosis and Haemostasis (ISTH) defined symptomatic venous thromboembolism
Time frame: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks
Risk (i.e., cumulative incidence) of Clinically relevant bleeding
International Society on Thrombosis and Haemostasis (ISTH) defined clinically relevant bleeding (Major bleeding + Clinically relevant Non-major bleeding)
Time frame: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks
Net Clinical Benefit - Modelled Attributable Risk Difference in HA-VTE (Efficacy) by Attributable Risk Difference in clinically relevant bleeding (Safety)
Net clinical benefit is a bivariate endpoint analysis (i.e., trade-off of venous thromboembolism and bleeding risks as described below). One-year risks and corresponding 95% confidence intervals (CI) of hospital-acquired venous thromboembolism and clinically relevant bleeding for each study arm will be calculated from weighted Kaplan-Meier curves. A bivariate decision curve will be specified using the 12-month absolute risk difference for venous thromboembolism and bleeding outcomes. Bivariate outcomes for enoxaparin and no pharmacological thromboprophylaxis will be compared under a hypothesis of superiority using the superiority boundary of a bivariate endpoint analysis, with inference based on the 95% confidence rectangle (i.e., the rectangle defined by the 95% CI for hospital-acquired venous thromboembolism absolute risk difference and the 95% CI for bleeding absolute risk difference). Superiority will be decided if the 95% confidence rectangle rules out the superiority curve.
Time frame: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks
Risk (i.e. cumulative incidence) of symptomatic venous thromboembolism
International Society on Thrombosis and Haemostasis-defined symptomatic venous thromboembolism
Time frame: From randomization through 30-days post discharge from the pediatric intensive care unit
Risk (i.e. cumulative incidence) of clinically relevant bleeding
International Society on Thrombosis and Haemostasis-defined clinically relevant bleeding (Major Bleeding + Clinically Relevant Non-Major Bleeding)
Time frame: From randomization through 30-days post discharge from the pediatric intensive care unit
Serious adverse events
As federally defined.
Time frame: From randomization through 30-days post discharge from the pediatric intensive care unit
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Start is estimated for Apr 2027; primary completion for Apr 2034, 84 months later.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 84 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin
Johns Hopkins All Children's Hospital